Volume 17, Issue 2 (5-2025)
IJDO 2025, 17(2): 76-78 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rafaiee R, Mousavi Bourkheili S M, Rafaiee R. Obesity Epidemic is an Introduction of Type 2 Diabetes Mellitus and Alzheimer's Epidemic. IJDO 2025; 17 (2) :76-78
URL: http://ijdo.ssu.ac.ir/article-1-949-en.html
URL: http://ijdo.ssu.ac.ir/article-1-949-en.html
MD, Ph.D., Psychiatry and Behavioral Sciences Research Center, Addiction Institute, Mazandaran University of Medical Sciences, Sari, Mazandaran, Iran.
Abstract: (54 Views)
The global rise of obesity has increased the prevalence of type 2 diabetes mellitus (T2DM) and the risk of Alzheimer’s disease (AD). The obesity, a key risk factor of T2DM, leads to insulin resistance, which contributes to cognitive decline and potentially AD through shared metabolic pathways. This Commentary highlights the connection between obesity, T2DM, and AD, suggesting that lifestyle changes like weight loss and discontinuation of sugar consumption may help to prevent these conditions. Comprehensive public health strategies focusing on diet, exercise, and education are essential to reduce the growing health crisis and improve metabolic and cognitive health globally.
Type of Study: Research |
Subject:
Special
Received: 2024/12/3 | Accepted: 2025/04/28 | Published: 2025/05/31
Received: 2024/12/3 | Accepted: 2025/04/28 | Published: 2025/05/31
References
1. Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ, et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9• 1 million participants. The lancet. 2011;377(9765):557-67. [DOI:10.1016/S0140-6736(10)62037-5]
2. Aaseth J, Ellefsen S, Alehagen U, Sundfør TM, Alexander J. Diets and drugs for weight loss and health in obesity-An update. Biomedicine & Pharmacotherapy. 2021;140:111789. [DOI:10.1016/j.biopha.2021.111789]
3. Mohajan D, Mohajan HK. Obesity and its related diseases: a new escalating alarming in global health. Journal of Innovations in Medical Research. 2023;2(3):12-23. [DOI:10.56397/JIMR/2023.03.04]
4. Scully T, Ettela A, LeRoith D, Gallagher EJ. Obesity, type 2 diabetes, and cancer risk. Frontiers in oncology. 2021;10:615375. [DOI:10.3389/fonc.2020.615375]
5. Chandrasekaran P, Weiskirchen R. The role of obesity in type 2 diabetes mellitus-An overview. International journal of molecular sciences. 2024;25(3):1882. [DOI:10.3390/ijms25031882]
6. Parekh J, Shende H, Kumar A, Tuli HS, Kaur G. Assessing the Clinical Correlation between Alzheimer's disease and Type-2 Diabetes Mellitus: Current Strategies and Emerging Perspectives. Current Pharmacology Reports. 2024;10(2):145-58. [DOI:10.1007/s40495-024-00354-2]
7. da Silva M, Fritz J, Mboya IB, Sun M, Wahlström J, van Guelpen B, et al. Cohort profile: the Obesity and Disease Development Sweden (ODDS) study, a pooled cohort. BMJ open. 2024;14(7):e084836. [DOI:10.1136/bmjopen-2024-084836]
8. Bednarz K, Siuda J. Alzheimer's disease and type 2 diabetes mellitus: similarities in pathomechanisms lead to therapeutic opportunities. Neurologia i Neurochirurgia Polska. 2021;55(5):418-28. [DOI:10.5603/PJNNS.a2021.0056]
9. Sędzikowska A, Szablewski L. Insulin and insulin resistance in Alzheimer's disease. International journal of molecular sciences. 2021;22(18):9987. [DOI:10.3390/ijms22189987]
10. Tyagi A, Pugazhenthi S. Targeting insulin resistance to treat cognitive dysfunction. Molecular neurobiology. 2021;58(6):2672-91. [DOI:10.1007/s12035-021-02283-3]
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |